|View printer-friendly version|
|La Jolla Pharmaceutical Company to Provide Corporate Overview at the Jefferies 2014 Global Healthcare Conference|
SAN DIEGO--(BUSINESS WIRE)--La Jolla Pharmaceutical Company (Nasdaq: LJPC) (the “Company” or “La Jolla”), a leader in the development of therapeutics targeting significant unmet life-threatening diseases, today announced that George Tidmarsh, MD, Ph.D., President and Chief Executive Officer, will provide a corporate overview at the Jefferies 2014 Global Healthcare Conference taking place June 2-5 in New York City.
About La Jolla Pharmaceutical Company
La Jolla Pharmaceutical Company is a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapeutics for chronic organ failure and cancer. GCS-100, the Company's lead product candidate, is a first-in-class inhibitor of galectin-3, a novel molecular target implicated in chronic organ failure and cancer. GCS-100 currently is in Phase 2 clinical development for chronic kidney disease (CKD). LJPC-501, the Company’s second product candidate, is a natural peptide for the potential treatment of hepatorenal syndrome. LJPC-401, the Company’s third product candidate, is a natural peptide for the potential treatment of iron overload. For more information on the Company, please visit http://www.ljpc.com.
|Print Page E-mail Page RSS Feeds E-mail Alerts IR Contacts|